Dr. Kennedy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
499 Jackson St
suite 300
San Francisco, CA 94111- Is this information wrong?
Summary
- Pediatric Infectious Diseases - academic training and experience.
Clinical Researcher, small and large molecule platforms and gene therapy with biologics, in pharmaceutical industry. Key contributor to development and launch of the sedative "Belsomra" or suvorexant (orexin antagonist).
Academic biochemist and structural biologist in macromolecular crystallography and 3D NMR spectroscopy.
Education & Training
- Yale-New Haven Medical CenterFellowship, Pediatric Infectious Diseases, 1998 - 2001
- Duke University HospitalInternship, Transitional Year, 1992 - 1993
- Stanford University School of MedicineClass of 1992
Certifications & Licensure
- TX State Medical License 2005 - 2024
- CT State Medical License 2001 - 2024
Clinical Trials
- Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers Start of enrollment: 2017 Jan 31
- A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus Start of enrollment: 2009 Sep 01
Publications & Presentations
PubMed
- 149 citationsStructural Insight into Processive Human Mitochondrial DNA Synthesis and Disease-Related Polymerase MutationsW. Dexter Kennedy, Y. Whitney Yin> ;Cell. 2009 Oct 16
- 23 citationsAssessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study.Kerri A. Schoedel, Hong Sun, Edward M. Sellers, Janice Faulknor, Naama Levy-Cooperman, Xiaodong Li, William P. Kennedy, Jang-Ho Cha, Nicole Lewis, Wen Liu, Phung Bondi...> ;Journal of Clinical Psychopharmacology. 2016 Aug 1
- 93 citationsIn Vivo Quantification of Calcitonin Gene-Related Peptide Receptor Occupancy by Telcagepant in Rhesus Monkey and Human Brain Using the Positron Emission Tomography Tra...Eric D. Hostetler, Aniket D. Joshi, Sandra Sanabria-Bohorquez, Hong Fan, Zhizhen Zeng, Mona Purcell, Liza Gantert, Kerry Riffel, Mangay Williams, Stacey O'Malley, Patr...> ;The Journal of Pharmacology and Experimental Therapeutics. 2013 Nov 1
- Join now to see all
Authored Content
- Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover StudyAugust 2016
Press Mentions
- Excision BioTherapeutics Appoints Biotechnology Industry Research & Development Veteran, William Kennedy, M.D., as Senior Vice President, Clinical DevelopmentApril 2nd, 2021
Grant Support
- Phase 1 Clinical Research Program for Functional Cure of HIV with in vivo Gene TherapyCalifornia Institute of Regenerative Medicine2022–2026
Research History
- Senior Vice President, clinical development at excision BiotherapeuticsHIV cure paradigm using CRISPRCas9 genome excision of provirus HIV1
Professional Memberships
- International AIDS SocietyMember
Industry Relationships
- Senior Vice President, Excision BiotherapeuticsFunctional cure of latent infectious diseases with CRISPR-SaCas9 [HIV, HBV, HSV]Disclosure: Excision Biotherapeutics- current2021 - Present
External Links
- ClinicalTrials.govhttps://clinicaltrials.gov/
- EBT-101https://clinicaltrials.gov/ct2/show/NCT05144386?term=EBT-101&draw=2&rank=1
- This is a FIH, open-label, sequential cohort, single ascending dose (SAD) study of EBT-101[CRISPR] for potential functional cure of HIV-1 subgroup B infected adults.https://clinicaltrials.gov/ct2/show/NCT05144386?term=EBT-101&draw=2&rank=1
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: